Cowen raises $1 bn royalty fund
This article was originally published in Scrip
Cowen Healthcare Royalty Partners has closed its second fund at nearly $1 billion, exceeding its $550 million target by more than 75%. Cowen Healthcare Royalty Partners II LP (CHRP II) will have a similar profile to the first fund, focusing on commercial stage biopharmaceutical and medical device companies in need of growth capital and universities and inventors looking to monetise product interests.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.